B cell epitope specificity in ANCA-associated vasculitis: Does it matter?

Clinical and Experimental Immunology

Volumn 137, Issue 3, 2004, Pages 451-459

  Van Der Geld, Y M ^a   Stegeman, C A ^a   Kallenberg, C G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

ANCA; ANCA associated vasculitis; Epitope spreading; MPO; PR3

Indexed keywords

EPITOPE; MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; B LYMPHOCYTE; DISEASE ACTIVITY; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; VASCULITIS; WEGENER GRANULOMATOSIS;

AMINO ACID SEQUENCE; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; EPITOPE MAPPING; EPITOPES, B-LYMPHOCYTE; HUMANS; MOLECULAR SEQUENCE DATA; MYELOBLASTIN; PEROXIDASE; PROTEIN STRUCTURE, QUATERNARY; SERINE ENDOPEPTIDASES; VASCULITIS;

EID: 4344602778     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2004.02572.x     Document Type: Review

References (77)

1. Borregaard N, Cowland J-B. Granules of the human neutrophilic polymorphonuclear leukocyte. Blood 1997; 89:3503-21.
2. Huffman GS, Specks U. Antineutrophil cytoplasmic antibodies. Arthritis Rheum 1998; 41:1521-37.
3. Gaskin G, Savage COS, Ryan JJ et al. Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis. Nephrol Dial Transplant 1991; 6:689-94.
4. Stegeman CA, Cohen Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CGM. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994; 120:12-7.
5. Slot MC, Tervaert JW, Boomsma MM, Stegeman CA. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum 2004; 51:269-73.
6. Cohen Tervaert JW, van der Woude FJ, Fauci AS et al Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med 1989; 149:2461-5.
7. Jayne DR, Gaskin G, Pusey CD, Lockwood CM. ANCA and predicting relapse in systemic vasculitis. Q J Med 1995; 88:127-33.
8. Boomsma MM, Stegeman CA, van der Leij MJ et al Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000; 43:2025-33.
9. Han WK, Choi HK, Roth RM, McCluskey RT, Niles JL. Serial ANCA titers: useful tool for prevention of relapses in ANCA-associated vasculitis. Kidney Int 2003; 63:1079-85.
10. Cohen Tervaert JW, Huitema MG, Hene RJ et al. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990; 336:709-11.
11. Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 1990; 87:4115-9.
12. Charles LA, Caldas ML, Falk RJ, Terrell RS, Jennette JC. Antibodies against granule proteins activate neutrophils in vitro. J Leukoc Biol 1991; 50:539-46.
13. Mulder AH, Heeringa P, Brouwer E, Limburg PC, Kallenberg CGM. Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA): a Fc gamma RII-dependent process. Clin Exp Immunol 1994; 98:270-8.
14. Savage COS, Pottinger BE, Gaskin G, Pusey CD, Pearson JD. Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity toward cultured endothelial cells. Am J Pathol 1992; 141:335-42.
15. Ewert BH, Jennette JC, Falk RJ. Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. Kidney Int 1992; 41:375-83.
16. Radford DJ, Savage CO, Nash GB. Treatment of rolling neutrophils with antineutrophil cytoplasmic antibodies causes conversion to firm integrin-mediated adhesion. Arthritis Rheum 2000; 43:1337-45.
17. Xiao H, Heeringa P, Hu P et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002; 110:955-63.
18. Liang B, Mamula MJ. Molecular mimicry and the role of B lymphocytes in the processing of autoantigens. Cell Mol Life Sci 2000; 57:561-8.
19. Craft J, Fatenejad S. Self antigens and epitope spreading in systemic autoimmunity. Arthritis Rheum 1997; 40:1374-82.
20. James JA, Harley JB. B cell epitope spreading in autoimmunity. Immunol Rev 1998; 164:185-200.
21. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002; 2:85-95.
22. Arbuckle MR, McClain MT, Rubertone MV et al Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349:1526-33.
23. James JA, Gross T, Scofield RH, Harley JB. Immunoglobulin epitope spreading and autoimmune disease after peptide immunization. Sm B/ B′-derived PPPGMRPP and PPPGIRGP induce spliceosome autoimmunity. J Exp Med 1995; 181:453-61.
24. Topfer F, Gordon T, McCluskey J. Intra- and intermolecular spreading of autoimmunity involving the nuclear self-antigens La (SS-B) and Ro (SS-A). Proc Natl Acad Sci USA 1995; 92:875-9.
25. Arbuckle MR, Reichlin M, Harley JB, James JA. Shared early autoantibody recognition events in the development of anti-Sm B/B′ in human lupus. Scand J Immunol 1999; 50:447-55.
26. Incaprera M, Rindi L, Bazzichi A, Garzelli C. Potential role of the Epstein-Barr virus in systemic lupus erythematosus autoimmunity. Clin Exp Rheumatol 1998; 16:289-94.
27. James JA, Neas BR, Moser KL et al. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum 2001; 44:1122-6.
28. Monneaux F, Muller S. Epitope spreading in systemic lupus erythematosus: identification of triggering peptide sequences. Arthritis Rheum 2002; 46:1430-8.
29. Pendergraft WF III, Preston GA, Shah RR et al Autoimmunity is triggered by cPR-3 (105-201), a protein complementary to human autoantigen proteinase-3. Nat Med 2004; 10:72-9.
30. van de Wiel BA, Dolman KM, van der Meer Gerritsen CH, von Hack CE, dem Borne AEGKr, Goldschmeding R. Interference of Wegeners granulomatosis autoantibodies with neutrophil proteinase 3 activity. Clin Exp Immunol 1992; 90:409-14.
31. Daouk GH, Palsson R, Arnaout MA. Inhibition of proteinase 3 by ANCA and its correlation with disease activity in Wegener's granulomatosis. Kidney Int 1995; 47:1528-36.
32. Van der Geld YM, Tool AT, Videler J et al Interference of PR3-ANCA with the enzymatic activity of PR3: differences in patients during active disease or remission of Wegener's granulomatosis. Clin Exp Immunol 2002; 129:562-70.
33. Dolman KM, Stegeman CA, van de Wiel BA et al. Relevance of classic anti-neutrophil cytoplasmic autoantibody (C-ANCA)-mediated inhibition of proteinase 3-alpha 1-antitrypsin complexation to disease activity in Wegener's granulomatosis. Clin Exp Immunol 1993; 93:405-10.
34. Falk RJ, Becker M, Terrell R, Jennette JC. Anti-myeloperoxidase autoantibodies react with native but not denatured myeloperoxidase. Clin Exp Immunol 1992; 89:274-8.
35. Chang L, Binos S, Savige J. Epitope mapping of anti-proteinase 3 and anti-myeloperoxidase antibodies. Clin Exp Immunol 1995; 102:112-9.
36. Griffin SV, Chapman PT, Lianos EA, Lockwood CM. The inhibition of myeloperoxidase by ceruloplasmin can be reversed by anti-myeloperoxidase antibodies. Kidney Int 1999; 55:917-25.
37. Chang L, Savige J. Studies to demonstrate inhibition of functional activity of neutrophil lysosomal enzymes with ANCA. Adv Exp Med 1993; 336:97-100.
38. Segelmark M, Persson B, Hellmark T, Wieslander J. Binding and inhibition of myeloperoxidase (MPO): a major function of ceruloplasmin? CHn Exp Immunol 1997; 108:167-74.
39. Goldschmeding R, van der School CE, ten Bokkel Huinink D et al. Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate- binding protein in the lysosomes of normal human neutrophils. J Clin Invest 1989; 84:1577-87.
40. Kao RC, Wehner NG, Skubitz KM, Gray BH, Hoidal JR. Proteinase 3. A distinct human polymorphonuclear leukocyte proteinase that produces emphysema in hamsters. J Clin Invest 1988; 82:1963-73.
41. Fujinaga M, Chernaia MM, Halenbeck R, Koths K, James MN. The crystal structure of PR3, a neutrophil serine proteinase antigen of Wegener's granulomatosis antibodies. J Mol Biol 1996; 261:267-78.
42. Rao NV, Rao GV, Marshall BC, Hoidal JR. Biosynthesis and processing of proteinase 3 in U937 cells. Processing pathways are distinct from those of cathepsin G. J Biol Chem 1996; 271:2972-8.
43. Garwicz D, Lindmark A, Hellmark T, Gladh M, Jogi J, Gullberg U. Characterization of the processing and granular targeting of human proteinase 3 after transfection to the rat RBL or the murine 32D leukemic cell lines. J Leukoc Biol 1997; 61:113-23.
44. Bini P, Gabay JE, Teitel A, Melchior M, Zhou JL, Elkon KB. Antineutrophil cytoplasmic autoantibodies in Wegener's granulomatosis recognize conformational epitope(s) on proteinase 3. J Immunol 1992; 149:1409-15.
45. Williams RC Jr, Staud R, Malone CC, Payabyab J, Byres L, Underwood D. Epitopes on proteinase-3 recognized by antibodies from patients with Wegener's granulomatosis. J Immunol 1994; 152:4722-37.
46. Griffith ME, Coulthart A, Pemberton S, George AJ, Pusey CD. Antineutrophil cytoplasmic antibodies (ANCA) from patients with systemic vasculitis recognize restricted epitopes of proteinase 3 involving the catalytic site. Clin Exp Immunol 2001; 123:170-7.
47. Van der Geld YM, Simpelaar A, Van Der Zee R et al. Antineutrophil cytoplasmic antibodies to proteinase 3 in Wegener's granulomatosis: epitope analysis using synthetic peptides. Kidney Int 2001; 59:147-59.
48. Selga D, Segelmark M, Wieslander J, Gunnarsson L, Hellmark T. Epitope mapping of anti-PR3 antibodies using chimeric human/mouse PR3 recombinant proteins. Clin Exp Immunol 2004; 135:164-72.
49. Sommarin Y, Rasmussen N, Wieslander J. Characterization of monoclonal antibodies to proteinase-3 and application in the study of epitopes for classical anti-neutrophil cytoplasm antibodies. Exp Nephrol 1995; 3:249-56.
50. Huang Z, Lockwood CM. Epitope mapping on Wegener's granulomatosis autoantigen proteinase 3. Chin Med J 2001; 114:760-3.
51. Rarok AA, Van der Geld YM, Stegeman CA, Limburg PC, Kallenberg CG. Diversity of PR3-ANCA epitope specificity in Wegener's granulomatosis. Analysis using the biosensor technology. J Clin Immunol 2003; 23:460-8.
52. Harmsen MC, Heeringa P, Van der Geld YM et al Recombinant proteinase 3 (Wegener's antigen) expressed in Pichla pastoris is functionally active and is recognized by patient sera. Clin Exp Immunol 1997; 110:257-64.
53. Van der Geld YM, Oost Kort WW, Limburg PC, Specks U, Kallenberg COM. Recombinant proteinase 3 produced in different expression systems: recognition by anti-PR3 antibodies. J Immunol Meth 2000; 244:117-31.
54. Szymkowiak CH, Johnston TW, Csernok E, Gross WL. Expression of the human autoantigen of Wegener's granulomatosis (PR3) in a baculovirus expression system. Biochem Biophys Res Commun 1996; 219:283-9.
55. Witko-Sarsat V, Halbwachs-Mecarelli L, Almeida RP et al. Characterization of a recombinant proteinase 3, the autoantigen in Wegener's granulomatosis and its reactivity with anti-neutrophil cytoplasmic autoantibodies. FEBS Lett 1996; 382:130-6.
56. Specks U, Pass DN, Fautsch MP, Hummel AM, Viss MA. Recombinant human proteinase 3, the Wegener's autoantigen, expressed in HMC-1 cells is enzymatically active and recognized by c-ANCA. FEBS Lett 1996; 390:265-70.
57. Van der Geld YM, Smook ML, Huitema MG, Harmsen MC, Limburg PC, Kallenberg CG. Expression of recombinant proteinase 3, the autoantigen in Wegener's granulomatosis, in insect cells. J Immunol Meth 2002; 264:195-205.
58. Sun J, Pass DN, Viss MA et al. A proportion of proteinase 3 (PR3)-specific anti-neutrophil cytoplasmic antibodies (ANCA) only react with Pr3 after cleavage of its N-terminal activation dipeptide. Clin Exp Immunol 1998; 114320-6.
59. Capizzi SA, Viss MA, Hummel AM, Pass DN, Specks U. Effects of carboxy-terminal modifications of proteinase 3 (PR3) on the recognition by PR3-ANCA. Kidney Int 2003; 63:756-60.
60. Specks U. What you should know about PR3-ANCA. Conformational requirements of proteinase 3 (PR3) for enzymatic activity and recognition by PR3-ANCA. Arthritis Res 2000; 2:263-7.
61. Moguilevsky N, Garcia Quintana L, Jacquet A et al. Structural and biological properties of human recombinant myeloperoxidase produced by Chinese hamster ovary cell lines. Eur J Biochem 1991; 197:605-14.
62. Tomizawa K, Mine E, Fujii A et al A panel set for epitope analysis of myeloperoxidase (MPO)-specific antineutrophil cytoplasmic antibody MPO-ANCA using recombinant hexamer histidine-tagged MPO deletion mutants. J Clin Immunol 1998; 18:142-52.
63. Fujii A, Tomizawa K, Arimura Y et al. Epitope analysis of myeloperoxidase (MPO) specific anti-neutrophil cytoplasmic autoantibodies (ANCA) in MPO-ANCA-associated glomerulonephritis. Clin Nephrol 2000; 53:242-52.
64. Audrain MA, Baranger TA, Moguilevski N et al. Anti-native and recombinant myeloperoxidase monoclonals and human autoantibodies. Clin Exp Immunol 1997; 107:127-34.
65. Short AK, Lockwood CM. Studies of epitope restriction on myeloperoxidase (MPO), an important antigen in systemic vasculitis. Clin Exp Jmmunol 1997; 110:270-6.
66. Patry YC, Nachman PH, Audrain MA, Falk RJ, Meflah K, Esnault VL. Difference in antigenic determinant profiles between human and rat myeloperoxidase. Clin Exp Immunol 2003; 132:505-8.
67. Russell KA, Pass DN, Specks U. Antineutrophil cytoplasmic antibodies reacting with the pro form of proteinase 3 and disease activity in patients with Wegener's granulomatosis and microscopic polyangiitis. Arthritis Rheum 2001; 44:463-8.
68. Chapman PT, Short AK, Lockwood CM. The use of biosensor technology in epitope mapping studies on human myeloperoxidase. Clin Exp Immunol 1998; 112:44.
69. Van der Geld YM, Limburg PC, Kallenberg CG. Proteinase 3, Wegener's autoantigen: from gene to antigen. J Leukoc Biol 2001; 69:177-90.
70. Dolman KM, Jager A, von Sonnenberg A, dem Borne AEGKr, Goldschmeding R. Proteolysis of classic anti-neutrophil cytoplasmic autoantibodies (C-ANCA) by neutrophil proteinase 3. Clin Exp Immunol 1995; 101:8-12.
71. Kaliyaperumal A, Michaels MA, Datta SK. Antigen-specific therapy of murine lupus nephritis using nucleosomal peptides. tolerance spreading impairs pathogenic function of autoimmune T and B cells. J Immunol 1999; 162:5775-83.
72. Eilat E, Dayan M, Zinger H. Mozes E. The mechanism by which a peptide based on complementarity-determining region-1 of a pathogenic anti-DNA auto-Ab ameliorates experimental systemic lupus erythematosus. Proc Natl Acad Sci USA 2001; 98:1148-53.
73. Hahn BH, Singh RR, Wong WK, Tsao BP, Bulpitt K, Ebling FM. Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus. Arthritis Rheum 2001; 44:432-41.
74. Sturrock AB, Franklin KF, Rao G et al. Structure, chromosomal assignment, and expression of the gene for proteinase-3. The Wegener's granulomatosis autoantigen. J Biol Chem 1992; 267:21193-9.
75. Bories D, Raynal MC, Solomon DH, Darzynkiewicz Z, Cayre YE. Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells. Cell 1989; 59:959-68.
76. Campanelli D, Melchior M, Fu Y et al. Cloning of cDNA for proteinase 3: a serine protease, antibiotic, and autoantigen from human neutrophils. J Exp Med 1990; 172:1709-15.
77. Hashinaka K, Nishio C, Hur SJ, Sakiyama F, Tsunasawa S, Yamada M. Multiple species of myeloperoxidase messenger RNAs produced by alternative splicing and differential polyadenylation. Biochemistry 1988; 27:5906-14.